Antibody generation
A fine-tuned protein large language model addresses inefficiencies in antibody discovery by generating diverse and functional human antibodies against various targets, overcoming limitations of conventional methods and AI-based techniques that rely on structure-based training data.
Patent Information
- Application Number
- PCT/US2025/030650
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-05-22
- Filing Date
- 2025-05-22
- Publication Date
- 2025-11-27
AI Technical Summary
Conventional antibody discovery methods are inefficient, costly, and limited by the need for large amounts of practical trial and error, while existing AI-based techniques struggle with complex biological datasets and require antibody-antigen structures that are less available than sequences, limiting their training data.
A computer-implemented method using a fine-tuned protein large language model (PLM) for autoregressive training on antigen-antibody sequences, enabling the generation of human antibodies without requiring antibody-antigen structures, and incorporating filtering and ranking criteria for humanness, germline identity, and mutational load.
The method generates diverse and functional human antibodies with demonstrated binding specificity against targets like SARS-CoV-2, H5N1, and RSV-A, showcasing efficient and accurate antibody design capabilities.